Literature DB >> 1350983

Aberrant interleukin (IL)-4 and IL-5 production in vitro by CD4+ helper T cells from atopic subjects.

P Parronchi1, M De Carli, R Manetti, C Simonelli, M P Piccinni, D Macchia, E Maggi, G Del Prete, M Ricci, S Romagnani.   

Abstract

The cytokine secretion profiles of T cell lines (TCL) specific for purified protein derivative (PPD) or streptokinase (SK), contemporarily derived from nine atopic and nine nonatopic individuals, were compared. Upon stimulation with phorbol myristate acetate (PMA) plus anti-CD3 monoclonal antibody (mAb), all TCL from both atopics and nonatopics produced interleukin (IL)-2 and interferon (IFN)-gamma. The mean IL-2 production by PPD- or SK-specific TCL from both atopics and nonatopics was similar, whereas the mean IFN-gamma production by TCL derived from atopics was significantly lower. In addition, both PPD- and SK-specific TCL from atopics produced detectable amounts of IL-4 and IL-5, whereas the corresponding TCL derived from nonatopics did not. A total number of 107 and 99 PPD-specific CD4+ T cell clones (TCC) were then derived from TCL of 4 atopic and 4 nonatopic donors and assessed for their profile of cytokine production in response to stimulation with either PMA plus anti-CD3 mAb or the specific antigen. Under both these experimental conditions, virtually all PPD-specific TCC from both atopic and nonatopic individuals produced IL-2 and IFN-gamma. In contrast, the great majority of PPD-specific TCC derived from nonatopic individuals did not produce IL-4 and IL-5, whereas high proportions of PPD-specific TCC derived from atopic donors displayed the ability to produce noticeable amounts of IL-4 and IL-5 besides IL-2 and IFN-gamma. These data indicate that CD4+ T cells from atopic individuals are able to produce IL-4 and IL-5 in response to bacterial antigens, such as PPD and SK, that usually evoke responses with a restricted type-1 T helper (Th1)-like cytokine profile in nonatopic individuals. Aberrant IL-4 production by Th cells may represent one of the immune alterations responsible for enhanced IgE antibody production in atopic people.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1350983     DOI: 10.1002/eji.1830220640

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  7 in total

Review 1.  IL-4: role in disease and regulation of production.

Authors:  P Choi; H Reiser
Journal:  Clin Exp Immunol       Date:  1998-09       Impact factor: 4.330

2.  IgE production in atopic patients is not related to IL-4 production.

Authors:  C T van der Pouw Kraan; R C Aalberse; L A Aarden
Journal:  Clin Exp Immunol       Date:  1994-08       Impact factor: 4.330

3.  Divergent T-cell cytokine patterns in inflammatory arthritis.

Authors:  A K Simon; E Seipelt; J Sieper
Journal:  Proc Natl Acad Sci U S A       Date:  1994-08-30       Impact factor: 11.205

Review 4.  Th1/Th2 balance in infection.

Authors:  C Infante-Duarte; T Kamradt
Journal:  Springer Semin Immunopathol       Date:  1999

Review 5.  Th2 cytokines and asthma. Interleukin-4: its role in the pathogenesis of asthma, and targeting it for asthma treatment with interleukin-4 receptor antagonists.

Authors:  J W Steinke; L Borish
Journal:  Respir Res       Date:  2001-02-19

6.  Serum Ghrelin Levels in Saudi Obese Asthmatic School-Children-Correlation with Interleukin-4, Interleukin-5, and Interleukin-21.

Authors:  Mohammed Saeed Al-Ayed; Khaled Sadeq Al-Shaibari; Dhafer Alshehri; Mohammed Jamaan Alzahrani; Iman Nasser; Hamdan Saad Alaamri; Wed Ahmad Alaseeri; Ahmed A Mahfouz; Saeed Ali Alsareii; Ahmed Morad Asaad; Aamir Magzoub; Mohammed Ansar Qureshi; Ehab Elagab; Elhashimi Eltayb Hassan; Mohammed Helmy Faris Shalayel
Journal:  Int J Environ Res Public Health       Date:  2020-03-04       Impact factor: 3.390

Review 7.  Biological roles of Yin Yang 2: Its implications in physiological and pathological events.

Authors:  Lang Li; Yanjun Li; Ian Timothy Sembiring Meliala; Vivi Kasim; Shourong Wu
Journal:  J Cell Mol Med       Date:  2020-09-23       Impact factor: 5.295

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.